Ivabradine Anpharm

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

ivabradine

Disponible depuis:

"Anpharm" Przedsiębiorstwo Farmaceutyczne S.A.

Code ATC:

C01EB17

DCI (Dénomination commune internationale):

ivabradine

Groupe thérapeutique:

Other cardiac preparations

Domaine thérapeutique:

Angina Pectoris; Heart Failure

indications thérapeutiques:

Symptomatic treatment of chronic stable angina pectorisIvabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.Treatment of chronic heart failureIvabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Descriptif du produit:

Revision: 9

Statut de autorisation:

Authorised

Date de l'autorisation:

2015-09-08

Notice patient

                                28
Classified as confidential by the European Medicines Agency
B. PACKAGE LEAFLET
29
Classified as confidential by the European Medicines Agency
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
IVABRADINE ANPHARM 5
MG FILM-COATED TABLETS
IVABRADINE ANPHARM 7.5
MG FILM-COATED TABLETS
ivabradine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Ivabradine Anpharm is and what it is used for
2.
What you need to know before you take Ivabradine Anpharm
3.
How to take Ivabradine Anpharm
4.
Possible side effects
5
How to store Ivabradine Anpharm
6.
Contents of the pack and other information
1.
WHAT IVABRADINE ANPHARM IS AND WHAT IT IS USED FOR
Ivabradine Anpharm (ivabradine) is a heart medicine used to treat:
-
Symptomatic stable angina pectoris (which causes chest pain) in adult
patients whose heart rate is
over or equal to 70 beats per minute. It is used in adult patients who
do not tolerate or cannot take
heart medicines called beta-blockers. It is also used in combination
with beta-blockers in adult
patients whose condition is not fully controlled with a beta-blocker.
-
Chronic heart failure in adult patients whose heart rate is over or
equal to 75 beats per minute. It
is used in combination with standard therapy, including beta-blocker
therapy or when beta-
blockers are contraindicated or not tolerated.
About stable angina pectoris (usually referred to as “angina”):
Stable angina is a heart disease which happens when the heart does not
receive enough oxygen. The
most common symptom of angina is che
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
Classified as confidential by the European Medicines Agency
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
Classified as confidential by the European Medicines Agency
1.
NAME OF THE MEDICINAL PRODUCT
Ivabradine Anpharm 5 mg film-coated tablets
Ivabradine Anpharm 7.5 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Ivabradine Anpharm 5 mg film-coated tablets
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride).
_Excipient with known effect: _
Each film-coated tablet contains 63.91 mg lactose monohydrate.
Ivabradine Anpharm 7.5 mg film-coated tablets
Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride).
_Excipient with known effect: _
Each film-coated tablet contains 61.215 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Ivabradine Anpharm 5 mg film-coated tablets
Salmon-coloured, oblong, film-coated tablet scored on both sides,
engraved with “5” on one face and
“S” on the other face.
The tablet can be divided into equal doses.
Ivabradine Anpharm 7.5 mg film-coated tablets
Salmon-coloured, triangular, film-coated tablet engraved with
“7.5” on one face and “S” on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic
stable angina pectoris in coronary
artery disease adults with normal sinus rhythm and heart rate ≥ 70
bpm. Ivabradine is indicated:
-
in adults unable to tolerate or with a contraindication to the use of
beta-blockers
-
or in combination with beta-blockers in patients inadequately
controlled with an optimal beta-
blocker dose.
3
Classified as confidential by the European Medicines Agency
Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure NYHA II to IV class
with systolic dysfunction, in adult
patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in
combination with standard therapy
including be
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 25-02-2019
Notice patient Notice patient espagnol 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 25-02-2019
Notice patient Notice patient tchèque 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 25-02-2019
Notice patient Notice patient danois 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation danois 25-02-2019
Notice patient Notice patient allemand 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 25-02-2019
Notice patient Notice patient estonien 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 25-02-2019
Notice patient Notice patient grec 28-02-2023
Notice patient Notice patient français 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation français 25-02-2019
Notice patient Notice patient italien 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation italien 25-02-2019
Notice patient Notice patient letton 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation letton 25-02-2019
Notice patient Notice patient lituanien 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 25-02-2019
Notice patient Notice patient hongrois 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 25-02-2019
Notice patient Notice patient maltais 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 25-02-2019
Notice patient Notice patient néerlandais 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 25-02-2019
Notice patient Notice patient polonais 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 25-02-2019
Notice patient Notice patient portugais 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 25-02-2019
Notice patient Notice patient roumain 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 25-02-2019
Notice patient Notice patient slovaque 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 25-02-2019
Notice patient Notice patient slovène 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 25-02-2019
Notice patient Notice patient finnois 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 25-02-2019
Notice patient Notice patient suédois 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 25-02-2019
Notice patient Notice patient norvégien 28-02-2023
Notice patient Notice patient islandais 28-02-2023
Notice patient Notice patient croate 28-02-2023
Rapport public d'évaluation Rapport public d'évaluation croate 25-02-2019

Rechercher des alertes liées à ce produit

Afficher l'historique des documents